

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Previously presented): A method of treating a neoplasm in a mammal in need thereof by providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor.

2 (Original): The method according to claim 1, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

3 (Original): The method according to claim 2, wherein the aromatase inhibitor is letrozole.

4 (Original): The method according to claim 1, wherein the neoplasm is renal cancer.

5 (Original): The method according to claim 1, wherein the neoplasm is soft tissue sarcoma.

6 (Previously presented): A method of treating breast cancer by providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor.

7 (Original): The method according to claim 1, wherein the neoplasm is a neuroendocrine tumor of the lung.

8 (Original): The method according to claim 1, wherein the neoplasm is cervical cancer.

9 (Original): The method according to claim 1, wherein the neoplasm is uterine cancer.

10 (Original): The method according to claim 1, wherein the neoplasm is a head and neck cancer.

11 (Original): The method according to claim 1, wherein the neoplasm is glioma.

12 (Original): The method according to claim 1, wherein the neoplasm is non-small cell lung cancer.

13 (Original): The method according to claim 1, wherein the neoplasm is prostate cancer.

14 (Original): The method according to claim 1, wherein the neoplasm is pancreatic cancer.

15 (Original): The method according to claim 1, wherein the neoplasm is lymphoma.

16 (Original): The method according to claim 1, wherein the neoplasm is melanoma.

17 (Original): The method according to claim 1, wherein the neoplasm is small cell lung cancer.

18 (Original): The method according to claim 1, wherein the neoplasm is ovarian cancer.

19 (Original): The method according to claim 1, wherein the neoplasm is colon cancer.

20 (Original): The method according to claim 1, wherein the neoplasm is esophageal cancer.

21 (Original): The method according to claim 1, wherein the neoplasm is gastric cancer.

22 (Original): The method according to claim 1, wherein the neoplasm is leukemia.

23 (Original): The method according to claim 1, wherein the neoplasm is colorectal cancer.

24 (Original): The method according to claim 1, wherein the neoplasm is unknown primary cancer.

25 (Previously presented): A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor, wherein either CCI-779, the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

26 (Original): The method according to claim 25 in which CCI-779 is provided in a subtherapeutically effective amount.

27 (Original): The method according to claim 25 in which the aromatase inhibitor is provided in a subtherapeutically effective amount.

28 (Original): The method according to claim 25 in which both CCI-779 and the aromatase inhibitor are provided in subtherapeutically effective amounts.

29 (Original): The method according to claim 25, wherein the aromatase inhibitor is letrozole.

30 (Original): An antineoplastic combination comprising an antineoplastic effective amount of a combination of CCI-779 and an aromatase inhibitor.

31 (Previously presented): A method of treating a neoplasm in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination consisting of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

32 (Previously presented): A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor.

33 (Original): The method according to claim 32, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

34 (Original): The method according to claim 33, wherein the aromatase inhibitor is letrozole.

35 (Currently amended): The method according to claim 32, wherein the estrogen receptor positive carcinoma is ~~of the breast cancer~~ or ovarian cancer.

36 (Original): The method according to claim 35, wherein the aromatase inhibitor is letrozole.

37 (Original): The method according to claim 32, wherein the CCI-779 or the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

38 (Previously presented): A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination consisting of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

Claims 39 – 44 (Cancelled).

45 (Previously presented): A pharmaceutical composition useful in treating a neoplasm in a mammal in need thereof, the composition consisting of (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase, excipients and/or a pharmaceutically acceptable carrier.

46 (Original): The pharmaceutical composition according to claim 45, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

47 (Original): The pharmaceutical composition according to claim 46, wherein the aromatase inhibitor is letrozole.

48 (Currently amended): An antineoplastic combination comprising an antineoplastic effective amount of a combination consisting of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

49 (New): A method of treating an estrogen receptor positive carcinoma of the breast in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor.